PROCEPT BioRobotics Corporation
PRCT
$59.03
$1.412.45%
| Weiss Ratings | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.19 | |||
| Price History | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.56% | |||
| 30-Day Total Return | -18.58% | |||
| 60-Day Total Return | -33.99% | |||
| 90-Day Total Return | -36.04% | |||
| Year to Date Total Return | -29.02% | |||
| 1-Year Total Return | 24.04% | |||
| 2-Year Total Return | 85.69% | |||
| 3-Year Total Return | 101.47% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -44.49% | |||
| 52-Week Low % Change | 26.47% | |||
| Price | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $103.81 | |||
| 52-Week Low Price | $45.56 | |||
| 52-Week Low Price (Date) | Apr 04, 2024 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.16B | |||
| Enterprise Value | 2.91B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.76 | |||
| Earnings Per Share Growth | -21.67% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 13.82 | |||
| Price/Book (Q) | 7.84 | |||
| Enterprise Value/Revenue (TTM) | 12.95 | |||
| Price | $59.03 | |||
| Enterprise Value/EBITDA (TTM) | -31.81 | |||
| Enterprise Value/EBIT | -30.09 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 53.84M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 232 7200 | |||
| Address | 150 Baytech Drive San Jose, CA 95134 | |||
| Website | www.procept-biorobotics.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -43.03% | |||
| Profit Margin | -40.71% | |||
| Management Effectiveness | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.86% | |||
| Return on Equity | -- | |||
| Income Statement | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 224.50M | |||
| Total Revenue (TTM) | 224.50M | |||
| Revenue Per Share | $4.17 | |||
| Gross Profit (TTM) | 137.10M | |||
| EBITDA (TTM) | -91.38M | |||
| EBIT (TTM) | -96.61M | |||
| Net Income (TTM) | -91.41M | |||
| Net Income Avl. to Common (TTM) | -91.41M | |||
| Total Revenue Growth (Q YOY) | 56.57% | |||
| Earnings Growth (Q YOY) | 31.44% | |||
| EPS Diluted (TTM) | -1.76 | |||
| EPS Diluted Growth (Q YOY) | 35.59% | |||
| Balance Sheet | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 333.73M | |||
| Cash Per Share (Q) | $6.20 | |||
| Total Current Assets (Q) | 481.84M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 402.22M | |||
| Current Ratio (Q) | 9.069 | |||
| Book Value Per Share (Q) | $7.35 | |||
| Total Assets (Q) | 534.02M | |||
| Total Current Liabilities (Q) | 53.13M | |||
| Total Debt (Q) | 82.25M | |||
| Total Liabilities (Q) | 131.80M | |||
| Total Common Equity (Q) | 402.22M | |||
| Cash Flow | PRCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -4.41M | |||
| Cash from Financing (TTM) | 180.13M | |||
| Net Change in Cash (TTM) | 76.50M | |||
| Levered Free Cash Flow (TTM) | -77.39M | |||
| Cash from Operations (TTM) | -99.21M | |||
